What results were seen in the 2-year open-label extension for ruxolitinib for vitiligo?

Featuring David Rosmarin, MD |

Vice Chair of Education and Research
Tufts Medical Center
Boston, MA

| Published May 01, 2024

Loading...

Related Media

Powered by Polaris TM
Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved